Most Read Articles
19 Sep 2018
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
09 Sep 2016
A German longitudinal study shows that Hodgkin’s lymphoma survivors experience acute and persistent fatigue regardless of tumour stage and treatment.
Natalia Reoutova, 6 days ago
Reduced conditioning intensity is significantly associated with increased relapse, decreased disease-free survival (DFS), and decreased overall survival (OS) in acute myeloid leukaemia (AML) patients with measurable residual disease (MRD), a new analysis of a phase III randomized clinical trial has shown.

Akt/mTOR, STAT3, ERK, PD-L1 expression linked to DFSP development, progression

21 Oct 2018

Local recurrence or metastasis of dermatofibrosarcoma protuberans (DFSP) may be predicted by complex factors beyond fibrosarcomatous subtype, according to a recent study.

Moreover, development and/or progression of DFSP appear to be associated with expression of protein kinase B (Akt)/mammalian target of rapamycin (mTOR), signal transducer and activator of transcription 3 (STAT3), extracellular signal regulated kinase (ERK) and programmed death ligand 1 (PD-L1).

Nine recurrent DFSPs had larger tumour size, deeper invasion beyond the subcutis and more diverse histologic subtype compared with 35 noncurrent DFSPs. The fibrosarcomatous subtype showed a high cyclin D1–positive index and frequent mitotic figures.

Two metastatic DFSPs (one each of the fibrosarcomatous and myxoid subtypes) revealed four and 11 instances of local recurrence, respectively. These DFSPs also demonstrated larger tumour size, deeper invasion beyond the subcutis and high expression of cyclin D1.

Expression of Akt/mTOR, STAT3, ERK and PD-L1 was none or low in the primary skin lesions and high in the corresponding metastatic sites. DFSP had more frequent expression of Akt/mTOR and ERK than did dermatofibroma.

In this study, the authors performed clinicopathologic and immunohistochemical analyses for 44 DFSPs having wide local excision and 92 dermatofibromas as controls to determine the features and key factors for adverse outcome in DFSP, as well as the implication of expression of Akt/mTOR, STAT3, ERK, cyclin D1 and PD-L1.

The study was limited by the lack of data on patients prior to hospital evaluation.

“Little is known regarding oncoproteins other than platelet-derived growth factor subunit B in DFSP. Moreover, the risk factors for worse prognosis are controversial,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
19 Sep 2018
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
09 Sep 2016
A German longitudinal study shows that Hodgkin’s lymphoma survivors experience acute and persistent fatigue regardless of tumour stage and treatment.
Natalia Reoutova, 6 days ago
Reduced conditioning intensity is significantly associated with increased relapse, decreased disease-free survival (DFS), and decreased overall survival (OS) in acute myeloid leukaemia (AML) patients with measurable residual disease (MRD), a new analysis of a phase III randomized clinical trial has shown.